Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/emerald-publishing/creating-a-national-champion-or-a-global-pharmaceutical-company-a-tale-208VkLVJwj
References (71)
-
L. Thomas (2004)
Are we all global now? Local vs. foreign sources of corporate competence: the case of the Japanese pharmaceutical industrySouthern Medical Journal, 25
-
Sophie Meunier (2000)
The French ExceptionForeign Affairs, 79
-
James Fanto (2002)
Persuasion and Resistance: The Use of Psychology by Anglo-American Corporate Governance Advocates in FranceCorporate Finance: Governance
-
B. Amable, Bob Hancké (2001)
INNOVATION AND INDUSTRIAL RENEWAL IN FRANCE IN COMPARATIVE PERSPECTIVEIndustry and Innovation, 8
-
Hans Schollhammer (1969)
National Economic Planning and Business Decision-Making: The French ExperienceCalifornia Management Review, 12
-
J. Peterson (1991)
Technology Policy in Europe: Explaining the Framework Programme and Eureka in Theory and Practice*Journal of Common Market Studies, 29
-
V. Schmidt (2002)
The Futures of European Capitalism -
김인영 (1998)
일본, 한국, 대만의 기업조직 : 제도의 관점에서, The Economic Organization of East Asian Capitalism Marco Orrù, by Nicole Woolsey Biggart and Gary G. Hamilton (Thousands Oaks, CA: Sage, 1997) -
R. Burt, R. Hogarth, C. Michaud (2000)
The Social Capital of French and American ManagersOrganization Science, 11
-
B. Colasse, P. Standish (1998)
State versus Market: Contending Interests in the Struggle to Control French Accounting StandardisationJournal of Management and Governance, 2
-
D. Mowery (2008)
Plus ca change: Industrial R&D in the “third industrial revolution”Industrial and Corporate Change, 18
-
P. Mustar, P. Larédo (2002)
Innovation and research policy in France (1980-2000) or the disappearance of the Colbertist stateResearch Policy, 31
-
J. Spencer, Thomas Murtha, S. Lenway (2005)
How Governments Matter to New Industry CreationAcademy of Management Review, 30
-
Geraldine Carminatti-Marchand, Mathieu Paquerot (2004)
THE COMPOSITION OF FRENCH BOARDS OF DIRECTORS: CHANGES SINCE 1995Corporate Ownership and Control, 1
-
D. Clark (1998)
The Modernization of the French Civil Service: Crisis, Change and ContinuityPublic Administration, 76
-
Kevin Sharer (2004)
A time for growth: an interview with Amgen CEO Kevin Sharer. Interview by Paul Hemp.Harvard business review, 82 7-8
-
Alistair Cole, Helen Drake (2000)
The Europeanization of the French polity: continuity, change and adaptationJournal of European Public Policy, 7
-
B. Colasse, P. Standish (2004)
The Development and Decline of Law in French Accounting RegulationJournal of Management and Governance, 8
-
K. Ruckman (2005)
Technology sourcing through acquisitions: evidence from the US drug industryJournal of International Business Studies, 36
-
H. Ehrmann (1961)
French Bureaucracy and Organized InterestsAdministrative Science Quarterly, 5
-
A. James (2002)
The Strategic Management of Mergers and Acquisitions in the Pharmaceutical Industry: Developing a Resource-based PerspectiveTechnology Analysis & Strategic Management, 14
-
H. Lüthy (1965)
De Gaulle: Pose and PolicyForeign Affairs, 43
-
Mary O’Sullivan (2003)
The political economy of comparative corporate governanceReview of International Political Economy, 10
-
A. Ades, R. Tella (1997)
National Champions and Corruption: Some Unpleasant Interventionist Arithmetic -
K. Douglas, R. Guell (2004)
The structural dynamics of the pharmaceutical industry An analysis of prescription drug costs in the United States & Canadian Markets -
Atul Nerkar, P. Roberts (2004)
Technological and product-market experience and the success of new product introductions in the pharmaceutical industrySouthern Medical Journal, 25
-
J. Zysman (1977)
The French state in the international economyInternational Organization, 31
-
L. Orsenigo, F. Pammolli, M. Riccaboni (2001)
Technological change and network dynamics: Lessons from the pharmaceutical industryResearch Policy, 30
-
W. Coleman, C. Chiasson (2002)
State power, transformative capacity and adapting to globalization: an analysis of French agricultural policy, 1960-2000Journal of European Public Policy, 9
-
G. Redding (2005)
The thick description and comparison of societal systems of capitalismJournal of International Business Studies, 36
-
Jeffrey Dyer, P. Kale, Harbir Singh (2004)
When to ally & when to acquire.Harvard business review, 82 7-8
-
Geoffrey Moore (2004)
Darwin and the demon: innovating within established enterprises.Harvard business review, 82 7-8
-
S. Anwar (2005)
EU's competition policy and the GE‐Honeywell merger fiasco: Transatlantic divergence and consumer and regulatory issuesThunderbird International Business Review, 47
-
S. Anwar (2007)
Global business and globalizationJournal of International Management, 13
-
C. Alcouffe (2000)
Judges and CEOs: French Aspects of Corporate GovernanceEuropean Journal of Law and Economics, 9
-
F. Rothaermel, David Deeds (2004)
Exploration and Exploitation Alliances in Biotechnology: A System of New Product DevelopmentStrategic Management Journal, 25
-
B. Quélin, C. Mothe (2000)
Creating competencies through collaboration:: The case of EUREKA R&D consortia -
M. Epstein (2005)
The determinants and evaluation of merger successBusiness Horizons, 48
-
V. Schmidt (2003)
French capitalism transformed, yet still a third variety of capitalismEconomy and Society, 32
-
10.1016/S0929-1199(02)00044-5
-
Detelina Marinova (2004)
Actualizing Innovation Effort: The Impact of Market Knowledge Diffusion in a Dynamic System of CompetitionJournal of Marketing, 68
-
Alexandra Waluszewski (2004)
A competing or co-operating cluster or seven decades of combinatory resources? What's behind a prospering biotech valley? $Scandinavian Journal of Management, 20
-
P. Hall (1988)
Governing the economy : the politics of state intervention in Britain and FranceAmerican Political Science Review, 82
-
Joel Baum, B. Silverman (2004)
Picking winners or building them? Alliance, intellectual, and human capital as selection criteria in venture financing and performance of biotechnology startupsJournal of Business Venturing, 19
-
M. Gittelman, B. Kogut (2003)
Does Good Science Lead to Valuable Knowledge? Biotechnology Firms and the Evolutionary Logic of Citation PatternsManag. Sci., 49
-
G. Fuchs (2001)
Introduction: Biotechnology in Comparative Perspective – Regional Concentration and Industry DynamicsSmall Business Economics, 17
-
Fiona Morton (2000)
Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industryInternational Journal of Industrial Organization, 18
-
M. Goyer (2001)
CORPORATE GOVERNANCE AND THE INNOVATION SYSTEM IN FRANCE 1985-2000Industry and Innovation, 8
-
Ha Hoang, F. Rothaermel (2005)
The Effect of General and Partner-Specific Alliance Experience on Joint R&D Project PerformanceAcademy of Management Journal, 48
-
10.1080/13662710125208
-
Joseph Bower (2001)
Not all M&As are alike--and that matters.Harvard business review, 79 3
-
V. Chiesa, G. Toletti (2004)
Network of Collaborations for Innovation: The Case of BiotechnologyTechnology Analysis & Strategic Management, 16
-
P. Allen, R. Ramlogan, S. Randles (2002)
Complex Systems and the Merger ProcessTechnology Analysis & Strategic Management, 14
-
(2000)
UNCTAD, World Investment Report 2000: Cross-border Mergers and Acquisitions and Development (Geneva and New York: United Nations, 2000). -
P. Ramirez (2006)
The globalisation of research in the pharmaceutical industry: A case of uneven developmentTechnology Analysis & Strategic Management, 18
-
J. Jenssen, G. Jorgensen (2004)
HOW DO CORPORATE CHAMPIONS PROMOTE INNOVATIONSInternational Journal of Innovation Management, 08
-
Bongjin Kim, J. Prescott (2005)
Deregulatory Forms, Variations in the Speed of Governance Adaptation, and Firm PerformanceAcademy of Management Review, 30
-
P. Ring, Gregory Bigley, T. D’Aunno, T. Khanna (2005)
PERSPECTIVES ON HOW GOVERMENTS MATTERAcademy of Management Review, 30
-
V. Schmidt (1996)
Loosening the Ties that Bind: The Impact of European Integration on French Government and its Relationship to BusinessJournal of Common Market Studies, 34
-
Nadine Roijakkers, J. Hagedoorn (2006)
Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networksResearch Policy, 35
-
Hee-jung Yeo, C. Pochet, A. Alcouffe (2003)
CEO Reciprocal Interlocks in French CorporationsJournal of Management and Governance, 7
-
V. Gilsing, B. Nooteboom (2006)
Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnologyResearch Policy, 35
-
M. Santoro, Joseph McGill (2005)
The effect of uncertainty and asset co‐specialization on governance in biotechnology alliancesSouthern Medical Journal, 26
-
N. Pangarkar (2003)
Determinants of Alliance Duration in Uncertain Environments: The Case of the Biotechnology SectorLong Range Planning, 36
-
P. Hall, D. Soskice (2001)
An Introduction to Varieties of Capitalism -
Alina Sorescu, Rajesh Chandy, Jaideep Prabhu (2003)
Sources and Financial Consequences of Radical Innovation: Insights from PharmaceuticalsJournal of Marketing, 67
-
Rita McGrath, Atul Nerkar (2004)
Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firmsSouthern Medical Journal, 25
-
(2002)
Total Global Strategy II -
H. Alexandre, Gerard Charreaux (2001)
Efficiency of French Privatizations: A Dynamic VisionIO: Regulation
-
Don Camara, Punit Renjen (2004)
The secrets of successful mergers: dispatches from the front linesJournal of Business Strategy, 25
-
R. Whitley (1991)
The Social Construction of Business Systems in East AsiaOrganization Studies, 12
- Publisher
- Emerald Publishing
- Copyright
- Copyright © 2008 Emerald Group Publishing Limited. All rights reserved.
- ISSN
- 0885-8624
- DOI
- 10.1108/08858620810913399
- Publisher site
- See Article on Publisher Site
Abstract
Purpose – The purpose of this illustrative case‐based research is to analyze and evaluate the 2004 controversial merger of two high‐profile French pharmaceutical companies, Sanofi‐Synthelabo and Aventis. Design/methodology/approach – This is a case‐based research paper that relates existing theory to mergers and acquisitions (M&As) and global strategies by highlighting those issues that impact business and industrial markets as well as multinational corporations' (MNCs) operations. Findings – Sanofi‐Aventis continues to go through a multitude of changes in its corporate reorganization while Novartis has been exploring collaborative ventures with pharmaceutical and bio‐tech companies. Research limitations/implications – There is a scarcity of published work in the case‐based research area. The work provides an understanding of the French government's national champion initiatives and their impact on the European and global pharmaceutical companies. Practical implications – The findings of this case have tangible implications for those business marketers and MNCs that operate in the European markets and other countries regarding seeking M&As and expansion. Originality/value – The case adds value in the national champion theory and its associated areas that relate to business and industrial markets.
Journal
Journal of Business and Industrial Marketing – Emerald Publishing
Published: Oct 10, 2008
Keywords: Pharmaceuticals industry; Acquisitions and mergers; France